GlassScriptPhysician profile
Paul X Li
NPI 1053325407
$14,911.30
in general payments reported to CMS, 2019-2025
36 companies · $1,558 in 2025
The $1,558 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,241 · 2020: $1,294 · 2021: $3,449 · 2022: $2,549 · 2023: $1,698 · 2024: $2,121 · 2025: $1,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,377.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $5,627.20 | 2019-2025 | Vemlidy |
| Amgen INC. | $1,462.72 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $1,031.98 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,029.26 | 2021-2025 | |
| Amarin Pharma, INC. | $698.84 | 2019-2023 | |
| Radius Health, INC. | $555.96 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $547.36 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $538.92 | 2019-2022 | |
| Lilly USA, LLC | $366.24 | 2019-2025 | Jardiance, Mounjaro |
| Nestle Healthcare Nutrition INC. | $336.97 | 2020-2022 | |
| Allergan, INC. | $314.42 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $299.85 | 2019-2023 | Belsomra |
| Sumitomo Pharma America, INC. | $294.73 | 2023-2025 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $213.19 | 2021-2022 | |
| Ardelyx, INC. | $174.75 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $145.32 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Ibsa Pharma INC. | $140.87 | 2021-2023 | Licart |
| Pfizer INC. | $138.98 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $137.77 | 2022-2023 | Unithroid |
| Biohaven Pharmaceutical Holding Company LTD. | $134.75 | 2022 | |
| Astellas Pharma US INC | $121.16 | 2019-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $104.21 | 2019-2024 | Xarelto |
| Hikma Pharmaceuticals USA | $98.80 | 2019-2022 | |
| Genentech USA, INC. | $57.24 | 2019-2020 | |
| Indivior INC. | $53.82 | 2019-2021 | |
| Orexo US, INC. | $53.05 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $42.94 | 2024 | Voquezna |
| Horizon Therapeutics Plc | $38.00 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $25.99 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $25.26 | 2019 | |
| Ironwood Pharmaceuticals, INC | $19.79 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.05 | 2024 | Jardiance |
| Vivus LLC | $17.24 | 2022 | |
| Redhill Biopharma INC. | $16.66 | 2021 | |
| Esperion Therapeutics, INC. | $16.30 | 2020 | |
| Eyevance Pharmaceuticals LLC | $12.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.